Abstract
In this study, we investigated the interactions ofp-fluorofentanyl, an opioid designer drug, fentanyl, sufentanyl, and morphine on cloned human μ-, κ-, and δ-opioid receptors coexpressed with heteromultimeric G protein-coupled inwardly rectifying K+ channels (GIRK1/GIRK2) and a regulator of G protein signaling (RGS4) in Xenopus oocytes. We demonstrate that p-fluorofentanyl more potently activates GIRK1/GIRK2 channels through opioid receptors than fentanyl and that the p-fluoro substitution also changes the potency profile from μ > κ > δ (fentanyl) to μ > δ ≥ κ (p-fluorofentanyl). A comparison of ligand efficacy revealed that morphine, fentanyl, and its analogs less efficiently activate GIRK1/GIRK2 channels through human μ-opioid receptor than [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin. Using site-directed mutagenesis, we investigated whether mutating residues Trp-318 and His-319 to their corresponding residues in κ- and δ-opioid receptors provides the molecular basis for μ/δ selectivity and μ/κ selectivity. Changes in EC50 values for the W318L and W318Y/H319Y μ-opioid receptors show a partial contribution of these residues to the decreased GIRK1/GIRK2 channel activation by fentanyl analogs through κ- and δ-opioid receptors. The most pronounced effect was observed forp-fluorofentanyl, suggesting that an interaction between the 4-fluorophenylpropanamide moiety of the drug and residues Trp-318 and His-319 is important for the resulting enhanced GIRK1/GIRK2 channel activation through the μ-opioid receptor. Finally, we demonstrate that mutation of W318L confers δ-like potency for morphine on the mutant μ-opioid receptor.
Footnotes
-
Send reprint requests to: Prof. Dr. Jan Tytgat, Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, University of Leuven, Van Evenstraat 4, B-3000 Leuven, Belgium. E-mail:Jan.Tytgat{at}farm.kuleuven.ac.be
- Abbreviations:
- GIRK
- G protein-coupled inwardly rectifying K+
- RGS
- regulators of G protein signaling
- hMOR
- human μ-opioid receptor
- hKOR
- human κ-opioid receptor
- hDOR
- human δ-opioid receptor
- DAMGO
- [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
- DPDPE
- [d-Pen2,d-Pen5]-enkephalin
- HK
- high potassium solution
- ND-96
- low potassium solution
- Received March 10, 2000.
- Accepted May 15, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|